Sign up to read this article for FREE!
After signing up, you'll start to receive regular news updates from us.
Peregrine Awarded Grant Under IRS Section 48D for Qualifying Therapeutic Discovery Projects
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Nearly all of this grant is available for immediate reimbursement and supports the following projects:
• Bavituximab for the treatment of patients with second-line non-small cell lung cancer
• Bavituximab for the treatment of patients with front-line non-small cell lung cancer
• Bavituximab for the treatment of patients coinfected with hepatitis C virus (HCV)/HIV
• Cotara® for the treatment of patients with glioblastoma multiforme (GBM)
"This award comes at an opportune time and will help further advance our clinical programs which have already shown clinical promise for addressing unmet medical needs in the treatment of cancer and viral infections," said Steven W. King, president and chief executive officer of Peregrine. "We are pleased to have been awarded the full available amount of this valuable non-dilutive funding for each of the four programs for which we applied."
• Bavituximab for the treatment of patients with second-line non-small cell lung cancer
• Bavituximab for the treatment of patients with front-line non-small cell lung cancer
• Bavituximab for the treatment of patients coinfected with hepatitis C virus (HCV)/HIV
• Cotara® for the treatment of patients with glioblastoma multiforme (GBM)
"This award comes at an opportune time and will help further advance our clinical programs which have already shown clinical promise for addressing unmet medical needs in the treatment of cancer and viral infections," said Steven W. King, president and chief executive officer of Peregrine. "We are pleased to have been awarded the full available amount of this valuable non-dilutive funding for each of the four programs for which we applied."
